Therapeutics Asset De-Risking: Strategies, Inflection Points and Requirements for IND Enablement

​Translating a promising scientific discovery into a viable therapeutic requires more than great science—it demands careful planning, strategic de-risking, and the right data at the right time. (We highly encourage our Blavatnik applicants to attend this session to strengthen their development plans.)

In this session, experts from DavosPharma will walk through the full trajectory from basic discovery through preclinical development, drug candidate nomination, and ultimately IND-enabling studies. The discussion will highlight key inflection points where different funding mechanisms—such as Blavatnik support, federal grants, and venture investment—can play a pivotal role.

Participants will receive a practical checklist of the critical studies and data packages needed at each stage to build a compelling case for their asset. The presentation will conclude with an interactive Q&A forum, offering investigators the opportunity to discuss challenges, ask questions, and explore strategies tailored to their own projects.

Please RSVP—lunch will be provided.